Moderna (MRNA) up 4% on report US is nearing a deal to green light a late-stage trial of mRNA pandemic bird flu vaccine

Moderna (NASDAQ: MRNA) up 4% as ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Next Articles